This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Lung Cancer  • Pulmonary Diseases  • Pulmonary Diseases, Other  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Athanassios Argiris, MD; Joan H. Schiller, MD

JAMA. 2004;292:499-500.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Lung cancer is a worldwide epidemic primarily caused by tobacco smoking.¹ Approximately 1 million new cases of lung cancer are diagnosed each year worldwide, resulting in more than 900 000 deaths.² Of these, approximately 175 000 new cases and 160 000 deaths occur annually in the United States.³ Unfortunately, late diagnosis of lung cancer is the rule, and no curative therapies exist for metastatic disease. Nevertheless, perceptible progress in the treatment of this disease has been made as the result of painstaking efforts and decades of clinical investigations.

The role of chemotherapy is now well established in essentially all stages of non–small-cell lung cancer (NSCLC). In advanced NSCLC, the superiority of chemotherapy over best supportive care alone has been repeatedly demonstrated in patients with good performance status.^4-6 If untreated, patients with metastatic NSCLC have a median survival of 4 to 5 months, with a 1-year survival . . . [Full Text of this Article]

Author Affiliations: Division of Hematology-Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern Unversity, Chicago, Ill (Dr Argiris) and Department of Medicine, University of Wisconsin Hospital, Madison (Dr Schiller).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer: A Meta-analysis
Catherine Delbaldo, Stefan Michiels, Nathalie Syz, Jean-Charles Soria, Thierry Le Chevalier, and Jean-Pierre Pignon
JAMA. 2004;292(4):470-484.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
Johnson
Clin. Cancer Res. 2006;12:4451s-4457s.
ABSTRACT | FULL TEXT  

Inhibitors of the Arachidonic Acid Pathway and Peroxisome Proliferator-Activated Receptor Ligands Have Superadditive Effects on Lung Cancer Growth Inhibition
Avis et al.
Cancer Res. 2005;65:4181-4190.
ABSTRACT | FULL TEXT